Jonathan Matlock
Co-Founder @ Empirical Ventures
Bedford, United Kingdom
Jonathan Matlock is a seed investor at Empirical Ventures in Bedford focused on Medical and Biotechnology. Co-Founder @ Empirical Ventures | Scientist | Entrepreneur | Investor | PhD Chemistry
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jonathan Matlock invests in
Stages Jonathan Matlock invests in
Countries Jonathan Matlock invests in
Investment Focus
Industry
- Medical 6 (50%)
- Biotechnology 4 (33%)
- Health Care 3 (25%)
- Medical Device 3 (25%)
- Life Science 2 (17%)
Stage
- Seed 10 (83%)
- Funding Round 2 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Healome Therapeutics
|
Healome Therapeutics | $2.7M / Seed / Jul 07, 2026 | |
Neuronostics
|
Neuronostics Ltd is a newly established University of Exeter (UK) spin-out, focussed on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP. | $4M / Seed / Jun 30, 2026 | |
Caudal Energy
|
Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics. | $5.8M / Seed / May 27, 2026 | |
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $6M / Jan 21, 2026 | |
EnsiliTech
|
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M / Seed / Aug 28, 2025 | |
OutSee
|
OutSee creates cutting-edge computational methods for genomics for the development of therapeutic targets and precision medicine. | $3.4M / Seed / Jun 24, 2025 | |
OSSTEC
|
OSSTEC is bringing advanced technology to the operating room with metal 3D printed bone healing implants. The orthopaedic implants emulate natural bone structure and address high failure rates of existing implants, keeping patients who suffer with osteoarthritis healthy, active and enjoying life. | $3.2M / Seed / Mar 30, 2025 | |
MintNeuro
|
MintNeuro is pioneering the use of semiconductor technology in next-generation neural implants. | $1.3M / Seed / Nov 12, 2024 | |
Argonaute RNA
|
Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. They show how their proprietary modification of smallinterfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. | $2.3M / Jul 17, 2024 | |
Halo Therapeutics
|
Halo Therapeutics develops antivirals to prevent users from sickness. It researches on virus shapes and creates fatty acids into medicine to lock them. Halo Therapeutics was founded in 2020 and is based in Bristol, England. | $1.9M / Seed / May 17, 2023 | |
| See all 12 investments → | |||
Co-Investors
About Empirical Ventures
Empirical Ventures supports innovative approaches to critical problems in the fields of biotechnology and life sciences.
Empirical Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jonathan Matlock
Co-Founder
|
|||
Johnathan Matlock
Co-Founder
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Jonathan Matlock invest in?
Jonathan Matlock invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Funding Round stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jonathan Matlock last invest?
The most recent investment recorded for Jonathan Matlock closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
